Evaluation of medical cost and clinical effect of new quadruple regimen for treatment of heart failure
Objective To investigate the medical cost and clinical efficacy of the new quadruple regimen with sodium-glucose linked transporter 2(SGLT2)inhibitor in treatment of heart failure(HF),and to provide economic reference for choosing treatment drugs for HF patients.Methods A total of 86 HF patients hospitalized in Ningbo Medical Center Lihuili Hospital from January 2022 to January 2023 were retrospectively selected as study objects.According to actual HF treatment regimen,the patients were divided into experimental group and control group,43 cases in each group.The experimental group received the new quadruple therapy regimen,and the control group received classical therapy regimen.Clinical efficacy,cardiovascular events and direct medical costs within 1 year were compared between two groups.Incremental cost-effectiveness ratio(iCER)was calculated,and sensitivity analysis was performed on the results.Results The direct medical costs of patients in experimental group were slightly higher than those in control group,but there was no statistically significant difference between two groups(¥12513.0 vs.¥11508.9,t=-0.079,P=0.125).There was no significant difference in total effective rate between experimental group and control group(81.40％vs.74.4％,x2=1.237,P=0.539).There was no significant difference in cardiovascular events within 1 year between two groups(x2=0.073,P=0.787).The cost-effectiveness ratio(C/E)of experimental group and control group were 15372.3 and 15468.9,respectively,and iCER was 143.5.Sensitivity analysis showed that the results were robust.Conclusion The clinical efficacy of control group and experimental group for HF was similar,but the C/E of experimental group was slightly higher than that of control group,and the new quadruple regimen with SGLT2 inhibitors had more pharmacoeconomic advantages.
万方数据
维普
